Multiple System Atrophy

MSA · Neurology · 1 drugs · 1 indications

Rare, rapidly progressive neurodegenerative disorder caused by alpha-synuclein accumulation. Affects movement, autonomic functions (blood pressure, bladder), and balance. No approved treatments.

Competitive Landscape (1 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Amlenetug	GMAB	Anti-alpha-synuclein monoclonal antibody	Antibody	IV	PHASE3

Indications (1)

Multiple System Atrophy

Amlenetug PHASE3

Data from Supabase · Updated 2026-03-24